With a market capitalization (market cap) of $10.23B — a measure of how much the company is worth — Summit Therapeutics Inc. is the 950th most valuable company in Healthcare as of August 18, 2026. Shares trade at $12.82, up +0.31% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Visit websiteAs of August 18, 2026, Summit Therapeutics Inc. (SMMT) is worth $10.23B — this is its market capitalization, the total value of all its outstanding shares.
Summit Therapeutics Inc.’s market cap is $10.23B, which ranks it #950 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Summit Therapeutics Inc. (SMMT) shares trade at $12.82, up 0.31% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025